Tyra Biosciences, Inc. (TYRA)
Develops precision cancer and genetic disorder drugs targeting FGFR protein mutations.
$30.86-0.01%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+197.5%
The outlook
TYRA trades at $30.86 with strong analyst support—12 analysts rate it a consensus Strong Buy. The stock sits roughly two-thirds of the way between its 52-week low and high, with the average analyst price target about 68% above current levels. Price momentum versus moving averages shows mixed signals, though the overall data leans bullish.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 12 analysts
Price trendMixed vs its moving averages
52-week range68% of the way from its 52-week low to high
Price targetAvg target +68% vs current price
Analyst price target
~12-month · 12 analysts$51.97average target+68.4% vs now
Now $30.86
Low $42.00High $59.62
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.83B
52-wk high
$40.65
52-wk low
$9.96
50-day avg
$30.95
200-day avg
$28.51
Trailing P/E
—